AMH levels in the blood serum of mice (n = 5/genotype/group) were determined by the automated Elecsys® AMH Plus immunoassay (Roche Diagnostics, Belgium) run on the cobas e 801 analytical unit (Roche Diagnostics) according to the manufacturer’s instructions. Analysis was performed by the LUHB laboratory (Brussels academic hospital laboratory).
Cobas e 801 analytical unit
Manufactured by Roche
Sourced in Switzerland
The Cobas e 801 analytical unit is a fully automated immunochemistry analyzer designed for clinical laboratories. It is capable of performing a wide range of immunoassay tests, including those for hormones, infectious diseases, and therapeutic drug monitoring. The Cobas e 801 offers high-throughput capabilities and is designed to deliver reliable and consistent results.
Automatically generated - may contain errors
Lab products found in correlation
Elecsys amh plus, by Roche (1 mentions)
Architect i2000sr immunoassay analyzer, by Abbott (1 mentions)
Elecsys gdf 15 assay, by Roche (1 mentions)
Anti sars cov 2 s, by Roche (1 mentions)
Elecsys anti sars cov 2 s assay, by Roche (1 mentions)
Advia 2400 clinical chemistry system, by Siemens (1 mentions)
7 protocols using cobas e 801 analytical unit
1
Automated Analysis of AMH Levels
2
Multimodal Hepatitis B Biomarker Profiling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Hepatitis B virus surface antigen, HBsAb, HBeAg, HBeAb, and HBcAb were measured by chemiluminescence using the Architect i2000SR Immunoassay Analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). Results of HBsAg were presented in IU/ml and HBsAb in mIU/ml, both with corresponding ranges. The results of HBeAg, HBeAb, and HBcAb were all presented in relative luminescence unit signal over cutoff ratio (s/co). Cutoff value and ranges were as follows: 0.05 and 0.0–250 IU/ml for HBsAg; 10 and 0.00–1,000.00 mIU/ml for HBsAb; 1.00 s/co as the cutoff for HBeAg and HBcAb, a value higher than 1.00 was considered as positive; 1.00 s/co set as the cutoff for HBeAb, a value higher than 1.00 were defined as negative. If a result fell in the gray zone, the sample was subjected to duplicate retesting and considered repeatedly reactive when both turned reactive. If both the retests were negative, we considered the original sample negative. When contradictory results appeared, we initiated external validation by Cobas e 801 analytical unit for immunoassay tests (Roche Diagnostics, Indianapolis, USA). HLA-B27 positivity was determined in the blood samples by the flow cytometric approach.
3
Biomarker Measurement for ABC-Bleeding Risk
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Three biomarkers were measured in the ABC-bleeding risk score (GDF-15, cTnT-hs, and hemoglobin). EDTA-anticoagulated blood samples were collected from the enrolled patients. Plasma samples were obtained following centrifugation and stored at −70°C until being analyzed centrally. GDF-15 level was analyzed using the Elecsys® GDF-15 assay (Roche Diagnostics International Ltd., Rotkreuz, Switzerland) with the same standardization as other routine reagents on cobas® e 801 analytical unit (Roche Diagnostics International Ltd., Rotkreuz, Switzerland). Other biomarkers included in the ABC-bleeding risk score were measured using the previously published method (10 (link), 11 (link)). All analyses were conducted according to manufacturer instructions.
4
Roche Elecsys Anti-SARS-CoV-2 Assay Validation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The Roche Elecsys Anti-SARS-CoV-2 assay uses a recombinant protein representing the nucleocapsid (N) antigen in a double-antigen sandwich assay format, which favors detection of high affinity antibodies against SARS-CoV-2. This immunoassay was performed by the Cobas e801 analytical unit (Roche), a high throughput immunochemistry module that uses the electrochemiluminescence technology. Roche Elecsys Anti-SARS-CoV-2 is validated for the use on human serum and plasma, providing a positive reaction against SARS-CoV-2 with a cut-off index over 1 (COI≥1). As the elution of the DBS leads to lower concentrations of antibodies in the eluate, a different cut-off was established as explained in more detail in the results section.
5
Quantifying SARS-CoV-2 Antibody Levels
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The Roche Elecsys anti-SARS-CoV-2 S assay uses a recombinant protein representing a truncated Spike (S) antigen in a double-antigen sandwich assay format, detecting antibodies of all subclasses against SARS-CoV-2. The immunoassay was performed on a Cobas e801 analytical unit (Roche) using the electrochemiluminescence (ELECSYS) technology. Roche Elecsys anti-SARS-CoV-2 S is a quantitative assay validated for use with human serum and plasma. The results are given in Units/mL, and for venous blood are equivalent to the standardized BAU. In this study, extensive validation was performed to provide quantitative readouts of the S1/RBD responses using the raw values obtained by the assay. DBS and venous blood matching pairs were measured on the same day with the same batch of ELECSYS Kit.
6
Serological Testing for COVID-19 Antibodies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Testing for humoral immunity was performed in the Clinical Institute for Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia, using Elecsys® Anti-SARSCoV-2 S assay (Roche Diagnostics Int, Rotkreuz, Switzerland). The assay was performed per the manufacturer's instructions, using Cobas e 801 analytical unit for immunoassay tests (F. Hoffmann-La Roche Ltd.). (https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html ) Antibody titer ≥0.8 U/mL was considered positive, as recommended by the manufacturer.
7
Prognostic Factors in Cervical Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The demographic characteristics, clinical characteristics, and laboratory results of the 178 patients were obtained from medical records. Data on age, body weight, tumor size, tumor stage, serum levels of squamous cell carcinoma (SCC) antigen, number of metastatic lymph nodes, serum albumin, and platelet, neutrophil, lymphocyte, and monocyte counts were collected. The International Federation of Gynecology and Obstetrics (FIGO) 2009 clinical staging system was used for tumor staging. Blood samples were collected before RT. Routine blood tests were performed using the Sysmex XN-9000 Hematology System (Sysmex Corporation, Shanghai, China). Biochemical tests were performed using an ADVIA 2400 Clinical Chemistry System (Siemens Healthineers, Erlangen, Germany). Serum SCC antigen tests were performed using a Cobas e 801 analytical unit (Roche Diagnostics International AG, Rotkreuz, Switzerland) and body weight was measured before treatment. The PNI and GNRI were calculated using the following formulas: PNI = serum albumin (g/L) + 5 × absolute lymphocyte count (109/L) and GNRI = [14.89 × serum albumin level (g/dL)] + [41.7 × actual body weight/ideal body weight]. NLR, PLR, and MLR were calculated as neutrophil/lymphocyte, platelet/lymphocyte, and monocyte/lymphocyte ratios, respectively.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!